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Smads are proteins that transduce signals on behalf of members of the TGFb superfamily of growth factors. Recently,
inhibitory Smads, Smad6, Smad7, and Dad, were isolated from human, mouse, and fly. These anti-Smads were shown to
inhibit TGFb signaling by stably associating to TGFb type I receptors or, as it was shown for Smad6, by binding to
receptor-activated Smad1. We report the cloning, distribution, and embryological activity of the Xenopus Smad7 (XSmad7).
We report that XSmad7 inhibits signaling from the activin and BMP pathways in animal explants although at different
thresholds. When expressed in the embryo, low concentrations of XSmad7 dorsalize the ventral mesoderm, thus inducing
a secondary axis. At higher concentrations however, XSmad7 inhibits both mesoderm induction and primary axis
specification. In addition, we show that XSmad7 acts as a direct neural inducer both in the context of ectodermal explants
and in vivo. We discuss the implications of these findings in the biochemical context of the activin and BMP pathways as
well as their implications in mesodermal, neural, and axis specification. © 1998 Academic Press
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INTRODUCTION
The TGFb superfamily of growth factors is involved in
biological activities that range from cell proliferation and
differentiation to regulation of developmental fate (Mas-
sague´ et al., 1997). In Xenopus laevis, members of this
family have been shown to be involved in inductive inter-
actions during early embryogenesis. These ligands interact
with two types of receptors (type I and type II) at the cell
surface (Massague´ and Weis-Garcia, 1996; ten Dijke et al.,
1996). After initial activation of the receptors, these induc-
tive signals are transduced from the cell membrane to the
nucleus by a family of proteins collectively known as
Smads.
Although structurally related, Smad proteins can be func-
tionally subdivided into three distinct classes: receptor-
regulated Smads, functional partners of receptor-regulated
Smads, and inhibitory or anti-Smads. Members of the first
class, Smad1, 2, 3, and probably 5 and 9, are directly
phosphorylated by activated TGFb type I receptors (Graff et
al., 1996; Hoodless et al., 1996; Kretzschmar et al., 1997;
Lechleider et al., 1996; Liu et al., 1996; Suzuki et al., 1997a;
Thomsen, 1996; Watanabe et al., 1997; Yingling et al., 1996,
Baker and Harland, 1996; Eppert et al., 1996; Macias-Silva
et al., 1996; Zhang et al., 1996). Smad1 and 5 transduce
signals on behalf of BMPs, while Smad2 and 3 mediate
signaling initiated by activins and TGFb proper. Upon
activation by the receptors, these Smads hetero-oligomerize
with Smad4 (the only known class two Smad), translocate
to the nucleus, and regulate transcription (Lagna et al.,
1996; Zhang et al., 1997). Inhibitory Smads (Smad6, Smad7,
and Dad) were recently identified (Topper et al., 1997;
Hayashi et al., 1997; Nakao et al., 1997; Imamura et al.,
1997; Tsuneizumi et al., 1997; Hata et al., 1998). There is
evidence that expression of both Smad6 and Smad7 down-
regulates transcriptional responses to TGFbs in cell culture.
Smad6 has been reported to associate with type I receptors
and inhibit Smad2 phosphorylation (Imamura et al., 1997)
and to bind and sequester phosphorylated Smad1, acting as
a decoy for Smad4 (Hata et al., 1998). Smad7 can likewise
bind stably to type I TGFb receptors thus precluding acti-
vation of receptor-regulated Smads (Hayashi et al., 1997;
Nakao et al., 1997). It was also reported that Smad7 inter-
acts with Smad6 but not with Smad1, 2, or 4 (Topper et al.,
1997). Smad7 and Dad were found to be transcriptionally
upregulated by TGFb ligands, suggesting that anti-Smads
could function as negative feedback regulators of TGFb
signaling (Nakao et al., 1997; Tsuneizumi et al., 1997). In
addition, when microinjected in Xenopus embryos, mouse
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Smad7 was shown to inhibit mesoderm formation (Nakao
et al., 1997).
We report here the cloning and functional characteriza-
tion of the Xenopus Smad7 (XSmad7). We show that in
animal cap explants, low doses of XSmad7 RNA block
BMP4, its constitutively active receptor ALK6, and its
signal transducer Smad1. At higher concentrations, XSmad7
is also able to inhibit activin protein, the constitutively
active receptor ALK4, and signal transducer Smad2. Ectopic
expression of XSmad7 in Xenopus embryos induces neural
tissue. Furthermore, XSmad7 microinjections into the ven-
tral marginal zone of Xenopus embryos induce partial
secondary axes. We also show that higher doses of XSmad7
microinjected radially or dorsally in the marginal zone
completely inhibit mesoderm induction. We conclude that
XSmad7 inhibits the activin/Smad2 and BMP/Smad1 sig-
naling pathways at different thresholds and can act as a
neural inducer.
MATERIALS AND METHODS
Cloning of XSmad7. By using a human liver cDNA library as a
template we amplified through PCR a 231-bp DNA fragment from
the C-terminal domain of human Smad7(amino acids 339–426).
This partial human Smad7 fragment was then used as a probe to
screen a Xenopus tailbud head library (Hemmati-Brivanlou et al.,
1991), from which five positive clones were isolated.
RT-PCR assays, primers, and conditions. The RT-PCR assays
were carried out according to the method described by Wilson and
Hemmati-Brivanlou (1995). XSmad7 was amplified with the fol-
lowing primers: upstream, 59-CCAACTTCTTCACGAGACTGG-
39; and downstream, 59-GCAGACTGTAAGCCTTCTCATAG-39.
Descriptions of the other primers used are found in the following
references: Xbra and NCAM (Suzuki et al., 1997a), cardiac actin
(Graff et al., 1996), globin (Hemmati-Brivanlou et al., 1990), OtxA
(Lamb et al., 1993), En2 (Hemmati-Brivanlou and Harland, 1989),
Krox20 (Bradley et al., 1992), HoxB9 (Wright et al., 1990), XSlug
(Nieto et al., 1994), Twist (Hopwood et al., 1989), EF1a (Gaff et al.,
1996), ODC (Suzuki et al., 1997b), and Vg1 (Weinstein et al., 1996).
RNA injections and animal cap assay. Unless specified other-
wise all microinjections were done with RNA and the amounts refer
to the total doses of RNA microinjected per embryo and not per
blastomere. The RNAs used for injections were synthesized in vitro in
the presence of cap analog, using the mMessage mMachine kit
(Ambion) and T3 (sense) or T7 (antisense) RNA polymerase. The DNA
templates were obtained by linearizing the pBluescriptSK construct
with XhoI (sense) or NotI (antisense, for in situ hybridization). To
assess secondary axis induction and mesoderm inhibition in vivo, we
coinjected XSmad7 RNA with nuclear b-galactosidase RNA (Smith
and Harland, 1991), used as lineage tracer, into the ventral and dorsal
vegetal blastomeres of four-cell-stage Xenopus embryos. The dorsal–
ventral polarity of albino embryos was judged by the size of animal
blastomeres. For the animal cap assay, we microinjected XSmad7
RNA at the animal pole of two-cell-stage embryos. We then explanted
the animal caps at the blastula stage and cultured them to the
indicated stage. The RNA extracted from the explants and control
embryos was reverse transcribed and amplified by PCR as described
above. In situ hybridization for both XSmad7 and Xbra was done as
previously described (Harland, 1991).
RESULTS
Cloning of Xenopus Smad7. To characterize the role of
Smad7 in vertebrate embryogenesis, we isolated the Xeno-
pus Smad7 cDNA. A partial human Smad7 cDNA obtained
by PCR was used as a probe to screen a Xenopus tailbud
head library (see Materials and Methods). Fifteen positive
clones were isolated and sequenced. Among some unknown
proteins, XSmad6 was isolated three times. One particular
clone was present five times. Its predicted open reading
frame (ORF) encoded a protein of 382 amino acids (Fig. 1A).
A database search with the nucleotide and the deduced
amino acid sequence established that this clone was indeed
related to both the human and mouse Smad7. Surprisingly,
short stretches of nucleotides in the 39 untranslated region
were found to be identical between Xenopus and human
(Fig. 1A, underlined). The Xenopus Smad7 protein is
smaller than its mammalian counterparts in that it lacks
several small domains in the N-terminal region (Fig. 1B).
These truncations lead to an amphibian Smad7 protein that
is 44 amino acids shorter than both the human and mouse
proteins (Topper et al., 1997; Nakao et al., 1997). [After
submission of this paper, an identical sequence was submit-
ted to GenBank under Accession No. AF026125].
Developmental expression of XSmad7. All the Smad
proteins isolated so far in Xenopus are expressed maternally
and maintain ubiquitous expression at least until gastrula-
tion when important cell fate decisions take place. Using a
set of XSmad7 specific primers we performed RT-PCR on
RNAs harvested from different stages of embryonic devel-
opment. Figure 2A shows that XSmad7 is expressed mater-
nally and that its expression is maintained until early
tailbud stages. To address the spatial distribution of
XSmad7, we performed whole-mount in situ hybridization.
RT-PCR analysis of dissected pieces derived from early
gastrula embryos (stage 10.25; Nieuwkoop and Faber, 1967)
showed that XSmad7 is ubiquitously expressed at these
stages (Fig. 2B). At neural plate stages (Fig. 3A), XSmad7
transcripts can be detected in the lateral edge of the anterior
neural plate (white arrowheads), as well as in the heart
primordia (black arrow), where expression persists until at
least the tailbud stages (see Fig. 3F). When the neural tube is
closed (Figs. 3B and 3C), XSmad7 is detected in the ventral
mesoderm including blood islands (Fig. 3C, red arrows),
heart (Figs. 3B and 3C, blue arrows), eyes, as well as a weak
expression in the hindbrain (black arrowheads in Fig. 3B and
white arrowhead in Fig. 3C). At tailbud stages (Figs. 3D and
3E), in addition to the region of expression described above,
the ventral expression of XSmad7 becomes restricted to the
blood islands (red arrows in Figs. 3D and 3E), in a pattern
reminiscent of the expression of globin transcripts
(Hemmati-Brivanlou et al., 1990), and the heart (Fig. 3E,
blue arrow). At tadpole stages (Fig. 3F), the strongest levels
of expression are found in the heart (blue arrow), the eyes, as
well as in the otic vesicle (black arrowhead).
XSmad7 inhibits the activin pathway. It was previ-
ously reported that mouse Smad7 could inhibit mesoderm
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induction in Xenopus embryos, suggesting that it may
interfere with the activin pathway (Nakao et al., 1996). We
tested here if our cloned Xenopus Smad7 could specifically
inhibit activin in embryonic explants and we achieved this
in three independent assays. We first challenged animal
caps which were incubated in the presence of activin
protein with increasing concentrations of XSmad7 RNA
(from 250 pg to 2 ng). Figure 4A shows that at concentra-
tions higher than 1 ng XSmad7 efficiently downregulates
mesoderm induction by activin. Second, we challenged the
activity of a constitutively active activin receptor, ALK4
(CA-ALK4, 1 ng), with 2 ng of XSmad7 RNA. Figure 4B
shows that the strong induction of the early pan-
mesodermal marker Xbra (Xbra) is inhibited when the
activated receptor is coexpressed with XSmad7 RNA. Fi-
nally, we show that XSmad7 (2 ng) inhibits signaling
FIG. 1. Structure of XSmad7. (A) Nucleotide and deduced amino acid sequence of XSmad7. The underlined nucleotides are identical to
sequences found in the 39 UTR of human Smad7. (B) Comparison of domain structures between Smad1, Smad6, Smad7, and Xsmad7, drawn
to scale. The amino- (N) and carboxy- (C) terminal homologous regions are shown as dark gray boxes. A region conserved only between
Smad6, Smad7, and XSmad7 is shown in black.
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downstream of the receptor by challenging the inducing
ability of Smad2 (1 ng, Fig. 4B and Fig. 4C), which trans-
duces signals on behalf of activin (Baker and Harland, 1996;
Massague et al., 1997). Our results indicate that XSmad7
can interfere with the activin pathway regardless of
whether it is activated by its extracellular ligand, the
activated receptor at the membrane level, or its signal
transducer intracellularly. These results are in agreement
with conclusions reached by ectopically expressing mouse
Smad7 in the marginal zone of Xenopus embryos (Nakao et
al., 1997).
XSmad7 neuralizes ectodermal explants. Since it was
reported that human and mouse Smad7 were inhibitors of
TGFb signaling (Nakao et al., 1997; Hayashi et al., 1997;
Topper et al., 1997), we examined the activity of XSmad7 in
the context of animal cap explants. Figure 5A shows that
injection of as little as 100 pg of XSmad7 RNA results in a
potent neural induction (lanes 1–3). The expression of
neural markers was direct in the sense that it was not
accompanied by mesoderm induction (see Fig. 4C, lane 2,
and Fig. 6B, lane 3). To further characterize the type of
neural tissue induced by XSmad7, we performed RT-PCR
with primers specific for a variety of neural markers. Figure
5B shows that XSmad7 (100 pg) induces the most anterior
type of neural tissue, as assessed by the upregulation of
OtxA transcripts (Lamb et al., 1993), while the mid-
hindbrain marker En2 (Hemmati-Brivanlou and Harland,
1989), the marker for rhombomeres 3 and 5 of the hind-
brain, Krox20 (Bradley et al., 1992), and the spinal chord
marker HoxB9 (Wright et al., 1990) are not detected. Also,
as it was the case with all other neural inducers identified
so far, no neural crest marker is induced, as the expression
of both XSlug (Nieto et al., 1994) and Twist (Hopwood et
al., 1989) remained unchanged. We conclude that XSmad7
can act as a direct neural inducer, generating the most
anterior neural tissue, the forebrain.
XSmad7 inhibits the BMP pathway. Since all neural
inducers reported so far neuralize animal explants by inhib-
iting the BMP pathway either extracellularly (noggin, Smith
and Harland, 1992; chordin, Sasai et al., 1994; follistatin,
Yamashita et al., 1997) or at the cell membrane (tAR,
Hemmati-Brivanlou and Melton, 1992; tBR, Graff et al.,
1994; Suzuki et al., 1995), we predicted that XSmad7 could
function as an inhibitor of the BMP pathway. We tested this
hypothesis directly by challenging the activity of BMP4, its
constitutively active receptor ALK6 [CA-ALK6 or BMPR-IB
(QD), Kretzschmar et al., 1997], as well as the activity of the
BMP signal transducer Smad1. BMP4 ligand, CA-ALK6, and
Smad1 have been previously shown to induce the ventral
type of mesoderm when expressed in animal cap explants
(Hata et al., 1998; Graff et al., 1996; Thomsen, 1996). As
with the activin pathway, we first challenged the BMP4
ligand (injected as RNA) with increasing concentrations of
XSmad7 (from 250 pg to 1.5 ng) in animal caps. Figure 6A
shows that the early mesoderm inducing activity of BMP4,
as assayed by the expression of Xbra (Smith et al., 1991) and
Xwnt8 (Christian et al., 1991), is inhibited by XSmad7 RNA
coinjected at concentrations as low as 0.25 ng. Consistent
with these results, the induction of early and late ventral
mesodermal markers by both CA-ALK6 and Smad1 (1 ng) is
inhibited or strongly downregulated in the presence of
XSmad7 (1 ng, Fig. 6B). These data suggest that in animal
cap explants XSmad7 can act as an inhibitor of the BMP
pathway. It is important to note that much higher concen-
trations of XSmad7 were necessary to downregulate activin
protein (compare Fig. 6A to Fig. 4A), as well as the consti-
FIG. 2. Developmental expression of XSmad7. (A) RT-PCR analysis of Xsmad7 expression during different stages of Xenopus development:
(2, 4) maternal, (8–9) blastula, (10–12.5) gastrula, and (14–19) neurula. Ornithine decarboxylase (ODC) is used as a loading control. (B)
Expression of XSmad7 in early gastrulae. Stage 10.25 embryos were dissected into animal–vegetal and dorsal–ventral halves, and total RNA
was harvested. The RNA was analyzed by RT-PCR for the distribution of Xsmad7 in different regions of the embryo. Vg1, chordin, and
Xwnt8 are dissection controls. Vg1 is localized in the vegetal pole, chordin is a marker of the organizer, Xwnt 8 is a marker of the ventral
mesoderm, and ODC is used as a loading control.
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tutively active ALK4 and Smad2 (compare the ratios used in
Fig. 4B to Fig. 6B).
Activity of XSmad7 in whole embryos. Our animal cap
assays suggested that XSmad7 could act as an inhibitory
Smad by blocking both BMP and activin signaling. To test
the effects of XSmad7 in vivo, we microinjected XSmad7
RNA into either the ventral or dorsal marginal zone of
four-cell-stage embryos. Expression of XSmad7 into ventral
blastomeres results in the induction of an incomplete
secondary axis in 85% of the cases (Fig. 7A; n 5 450). As the
concentration of XSmad7 RNA was increased (from 0.1 to
0.3 ng) the percentage of embryos displaying secondary axes
decreased to 40–50% (n 5 200). When this experiment was
repeated in the presence of a lineage tracer such as nuclear
b-galactosidase (b-Gal), we found that the lineage of the
injected cells contributed to the ectopic axis (Fig. 7D).
Dorsal microinjections of XSmad7 RNA in the marginal
zone of four-cell-stage embryos did not result in any marked
phenotype (Figs. 7C and 7E). Examination of the lineage
tracer in embryos coinjected dorsally with b-Gal and
XSmad7 showed that the progeny of the dorsal blastomeres
expressing XSmad7 contributed to the main axis and the
FIG. 3. Localization of XSmad7 transcripts in Xenopus embryos. Whole-mount in situ hybridization showing the localization of XSmad7
at different stages of Xenopus development. At neural plate stages (A), XSmad7 transcripts can be detected in the lateral edge of the anterior
neural plate (white arrowheads), as well as in the heart primordium (black arrowhead). Anterior is to the right and dorsal is facing the reader.
When the neural tube is closed (B and C), XSmad7 is strongly expressed in the ventral mesoderm, including the blood islands (C, red
arrowheads), heart (B and C, blue arrows), eyes (B and C), and hindbrain (black arrowheads in B and white arrowhead in C). B is a head-on
view and C is a lateral view. At tailbud stages (D and E) the ventral expression of XSmad7 is detected in the blood islands (red arrows, D
and E), in a pattern reminiscent of the expression of globin transcripts (Hemmati-Brivanlou et al., 1990). Strong expression in the heart is
maintained (blue arrow in E). D is a side view and E is a ventral view. At tadpole stages (F), the strongest levels of expression remain in the
heart (blue arrow), the eyes, and the otic vesicle (black arrowhead).
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head (Fig. 7C). In all embryos injected with b-Gal, XSmad7,
or a combination of both, the numbers of nuclei staining
positive for b-Gal were comparable, suggesting that no
major cell death occurred due to the injections. Staining of
the secondary axes revealed the presence of neural tissue
(N-CAM, Fig. 7F) with little or no muscle or notochord (Fig.
7H and data not shown).
To further test the ability of XSmad7 to induce neural tissue
in the whole embryo, we expressed XSmad7 RNA in the
animal poles of two-cell-stage embryos. When they reached
tadpole stages, injected embryos developed exaggerated neural
tissue, including ectopic eyes (Fig. 7J). This parallels observa-
tions made with the truncated activin receptor (Hemmati-
Brivanlou and Melton, 1994). Altogether these data show that
Xsmad7 can act as a neural inducer in vivo and, when
expressed in the ventral marginal zone, induce secondary axes
containing mostly neural tissue.
To determine the effects of XSmad7 in mesoderm induction
in the embryo we microinjected XSmad7 RNA (50 to 400 pg,
n 5 450) at increasing concentrations in the marginal zone of
four-cell-stage embryos either dorsally or radially. These em-
bryos were examined at early gastrula stages for the expression
of the early pan-mesodermal marker Xbra and at tadpole
stages by phenotypic inspection. Xenopus mesoderm induc-
tion is characterized by the appearance of Xbra transcripts in
the marginal zone of the early gastrula (Smith et al., 1991).
Marginal zone microinjection of molecules that disrupt me-
soderm induction, such as dominant negative activin recep-
tors (Hemmati-Brivanlou and Melton, 1992; Chang et al.,
1997; Dyson and Gurdon, 1997) or dominant negative Smad4
(Lagna et al., 1996), downregulates transcription of Xbra at
gastrula stages. We therefore made use of this assay to test if
FIG. 4. Inhibition of the activin pathway by XSmad7. (A) XSmad7 RNA-injected or uninjected animal caps were cultured until stage 23 in the
presence (lanes 1 to 6) or absence (lane 7, control) of activin protein (1/1000 dilution of activin-injected oocyte supernatant). EF1a, which is
ubiquitously expressed, was used as a loading control. RNA from embryos provides a positive control. The RT- lane is identical to that of the
embryo with the omission of reverse transcriptase, thus serving as a negative control. Uninjected animal caps cultured in the presence of activin
protein express the dorsal mesoderm-specific marker cardiac actin (C. Actin), which is gradually downregulated by injection of XSmad7 RNA
(0.25 to 2 ng). Similarly, animal caps injected with 1 ng of constitutively active activin receptor ALK4 (CA-ALK4) or its signal transducer Smad2
induce the general mesoderm marker Xbra at gastrula stages (lanes 1 and 2, B) and the dorsal mesoderm marker cardiac actin at neurula stages
(lane 1, C). These inductions are efficiently inhibited by coinjections of 2 ng of XSmad7 RNA (lanes 4 and 5, B; and lane 3, C).
FIG. 5. XSmad7 induces anterior neural tissue. (A) Animal caps
were injected with 0.1, 0.4, and 2 ng of XSmad7 RNA. Total RNA was
harvested at stage 16 (neurula) and analyzed by RT-PCR for the
presence of the indicated transcripts. XSmad7 alone induces the
expression of the neural marker NCAM in a concentration-dependent
manner. (B) Animal caps injected with 1 ng of XSmad7 were cultured
until sibling embryos reached stage 16. By using specific primers in
RT-PCR assays we show that XSmad7 induces anterior neural mark-
ers OtxA (a marker of forebrain, midbrain, and eyes; Lamb et al., 1993)
but not Engrailed-2 (En2, a marker of midbrain–hindbrain), Krox20
(hindbrain marker), HoxB9 (spinal cord and posterior lateral meso-
derm marker), or Xslug or Twist (markers of neural crest).
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XSmad7 would also disrupt early mesoderm induction. Figure
8A shows that embryos microinjected with b-Gal alone in the
dorsal marginal zone of four-cell-stage embryos reveal the
typical ring of Xbra expression. However, coexpression from
as little as 50 pg of XSmad7 (Fig. 8C) to 400 pg (Fig. 8E)
precluded Xbra transcription at the site of injection as mea-
sured at gastrula stages. When XSmad7/b-Gal RNA was
coinjected in the marginal zone of all four cells of fertilized
Xenopus embryos, the Xbra ring completely disappeared (Fig.
8G, 300 pg).
To assay the effect of XSmad7 at later stages we allowed
embryos microinjected with XSmad7/b-Gal RNA dorsally
or radially in the marginal zone to develop up to tailbud
stages (stage 28). We found that embryos injected dorsally
with low concentrations of XSmad7/b-Gal did not show
any marked phenotype (Fig. 8C, 50 pg). As the concentra-
tion of the microinjected RNA was increased (300–400 pg),
embryos displayed a reduction of the primary axis (Fig. 8F,
350 pg). When XSmad7/b-Gal RNA was injected radially in
the marginal zone (200–400 pg) or dorsally at high concen-
trations (500 pg), mesoderm induction was completely
abolished in 85% of the embryos (Fig. 8H and data not
shown) resulting in the formation of ‘‘bubble’’ embryos
(Hemmati-Brivanlou and Melton, 1992). Altogether these
FIG. 6. XSmad7 blocks the BMP pathway in animal cap explants. (A) BMP4 RNA (1 ng) was injected alone or coinjected with increasing
concentrations of XSmad7 RNA in the animal poles of two-cell-stage embryos. Animal cap explants from these embryos were cultured until
midgastrula stages, when RNA was extracted, reverse transcribed, and amplified by PCR in the presence of Xbra and Xwnt8 specific
primers. Although BMP4 alone is able to induce these markers (lane 1), in the presence of as low as 0.25 ng of XSmad7, this induction is
completely abolished. (B) As previously reported, constitutively active BMP receptor ALK6 [CA-ALK6 (1 ng), Kretzschmar et al., 1997] as
well as its signal transducer Smad1 [(1 ng), Graff et al., 1996] induces early (Xbra and Xwnt8, at gastrula stages) and late (globin, late neurula
stages) ventral mesoderm markers in animal caps (lanes 1 and 2). As shown with BMP4 in A, these inductive events are blocked in the
presence of XSmad7 (1 ng, lanes 4 and 5).
FIG. 7. XSmad7 induces secondary axes and ectopic neural tissue in vivo. XSmad7 RNA (0.1–0.3 ng) was injected alone (A) or coinjected
with nuclear b-Gal RNA (100 pg) into the dorsal (C) or ventral marginal zone (D) of four-cell-stage embryos. Unlike control b-Gal (B) or
XSmad7/b-Gal dorsal injections (C), ventral expression of XSmad7 or XSmad7/b-Gal RNA induced ectopic secondary axes in embryos (D,
F, and H). b-Galactosidase staining of injected embryos revealed that the progeny of the injected blastomere contributed directly to the
secondary axis (D). N-CAM staining of XSmad7 ventrally injected embryos (F) shows that the secondary axis contains neural tissue; E
corresponds to XSmad7 dorsally injected controls. Muscle actin staining shows that although muscle is present in the primary axis
[arrowheads, G (control) and H (ventral injection)], this expression is absent in the secondary axis (H and data not shown). Animal pole
injections of XSmad7 RNA in two-cell-stage embryos induce exaggerated neural tissue at tadpole stages, including the formation of ectopic
eyes (J, arrowhead). (I) Uninjected control.
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FIG. 8. Mesoderm inhibition by XSmad7. XSmad7 RNA (50–400 pg) was either injected alone or coinjected with the lineage tracer b-Gal
(same concentrations) dorsally or radially in the marginal zone of four-cell-stage embryos. Embryos were cultured until gastrula stage 10.5
(A, C, E, and G, vegetal pole view) or stage 28 (B, D, F, and H). Stage 10.5 embryos were stained for b-Gal (red) and assayed for Xbra expression
by whole-mount in situ hybridization (blue). Although embryos injected dorsally with b-Gal alone displayed the typical Xbra ring (A),
coinjections in the dorsal marginal zone with 50 or 400 pg (C and E, respectively) of XSmad7 inhibited Xbra at the site of injection (shown
with arrowheads). Radial coinjections (300 pg) completely abolished Xbra expression (G). At tadpole stages, dorsal injections of
XSmad7/b-Gal (50 pg) had no visible effects (D). At higher concentrations of XSmad7, embryos showed a reduction in the primary axis (350
pg, F). Radial injections of XSmad7 (300 pg) completely inhibited mesoderm induction leading to the formation of ‘‘bubble’’ embryos (H,
animal pole view).
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data indicate that XSmad7 is capable of inhibiting meso-
derm induction in vivo.
DISCUSSION
We have identified the Xenopus homologue of the
mammalian Smad7. All XSmad proteins identified to
date show a high degree of amino acid conservation when
compared to their mammalian counterparts. The overall
sequence similarity between Smad1 and XSmad1 is ap-
proximately 95%. XSmad7 is unusual in that its
C-terminal domain (MH2) is 93% identical to human or
mouse Smad7, but its N-terminal domain is only 52%
identical. Recent biochemical studies may provide an
explanation for the high conservation of the Smad7 MH2
domain among species. Hayashi et al. (1997) showed that
truncation of this domain disrupts Smad7 binding to the
receptor, thus nullifying its inhibitory function. Interest-
ingly, we have identified nucleotide sequences at the 39
UTR of XSmad7 which are identical in human Smad7.
These sequences might be involved in regulatory func-
tions such as RNA stability.
We challenged both the BMP and activin pathways in
animal cap explants by coexpressing XSmad7 with ac-
tivin or BMP4, the activated receptors ALK6 and ALK4,
and their downstream signal transducers Smad1 and
Smad2. Our studies show that XSmad7 inhibits induction
from both pathways, although at different thresholds (see
below). Our data do not address how XSmad7 acts as an
inhibitory Smad, but based on its structural similarity
with the mammalian Smad6 and Smad7, two different
but not necessarily exclusive mechanisms are possible.
First, XSmad7 could associate with TGFb family recep-
tors and interfere with phosphorylation of receptor-
regulated Smads, a mechanism proposed to explain the
inhibitory effects of Smad6 and Smad7 (Imamura et al.,
1997; Hayashi et al., 1997; Nakao et al., 1997). Alterna-
tively, XSmad7 could interact with receptor-regulated
Smads yielding transcriptionally inactive complexes, as
it has been proposed for Smad6 (Hata et al., 1998). In our
experiments, both mechanisms could account for the
inhibition of constitutively active receptors and signal
transducers. Future studies would be necessary to dis-
criminate between these possibilities.
We have shown that ventral marginal zone expression of
low concentrations of XSmad7 RNA induces the secondary
axis, consistent with its inhibition of the BMP pathway in
animal caps. Increasing the concentration of XSmad7 in the
ventral marginal zone decreases the percentage of animals
displaying an ectopic axis. At low doses, dorsal marginal zone
expression of XSmad7 inhibits initial mesoderm induction in
vivo, as seen by its repression of Xbra transcripts during
gastrulation. We showed that these embryos eventually re-
cover and develop normally. At higher concentrations how-
ever, dorsal or radial expression of XSmad7 in the marginal
zone completely abolishes formation of the mesoderm. Alto-
gether these data suggest that XSmad7 affects distinct TGFb
pathways at different thresholds: at low doses it selectively
blocks the BMP pathway, whereas at higher concentrations it
is also capable of inhibiting the activin/TGFb-like pathways.
This threshold effect was also mimicked in the animal cap
assays where concentrations of XSmad7 that clearly abolish
BMP signaling were insufficient to downregulate the activin
pathway. We have also observed that increasing the dose of
XSmad7 RNA injected ventrally in the marginal zone de-
creases the percentage of embryos displaying an ectopic axis.
It is possible that at these concentrations, in addition to
inhibiting the BMP pathway, XSmad7 blocks activin/TGFb-
like signals that might be necessary to generate the secondary
axis. Our data do not address which signaling pathway
XSmad7 affects in vivo.
It is interesting to note that the inhibition of early
mesoderm formation by low concentrations of XSmad7 did
not seem to affect embryonic development. This observa-
tion could be explained by the existence of secondary
mechanisms, which are not inhibited by XSmad7 and
compensate for the initial inhibition of the dorsal meso-
derm. Compensatory pathways in development are not
uncommon. Selective inhibition of activin by a soluble
form of its receptor (ActRIIBexd) precludes early Xbra
transcription, although wild-type levels of expression are
reached later in development, presumably by an alternative
mechanism (Dyson and Gurdon, 1997).
Our data show that XSmad7 RNA is present maternally
and maintains a ubiquitous expression at least until the
onset of gastrulation when the mesoderm, ectoderm, and
endoderm are specified. Since we have shown that
XSmad7 can efficiently block BMP and activin signaling,
the question then is how does a maternally present
XSmad7 allow any signaling among cells? One possibility
is that the concentration of XSmad7 present in the
embryo is not enough to exert a complete inhibition, but
simply to downregulate or control the levels of TGFb
signaling. Conversely, XSmad7 transcripts and/or protein
could be restrained by another inhibitor, a restriction
that we have overcome by microinjections of XSmad7
RNA. Cell culture experiments indicate that anti-Smad
transcripts are induced in response to TGFb ligands,
suggesting that inhibitory Smads act in a negative-
feedback loop to control TGFb signaling (Nakao et al.,
1997; Tsuneizumi et al., 1997). It would be interesting to
know if XSmad7 is transcriptionally induced by BMPs,
activin, or other members of the TGFb superfamily such
as Xnrs or Vg1. Our in situ hybridization shows that, at
least in blood islands and the heart, the pattern of
expression of XSmad7 coincides with that of BMP4
(Hemmati Brivanlou and Thomsen, 1995).
Finally, we showed that in both ectodermal explants and
embryo expression of XSmad7 induce the formation of
neural tissue. The default model of neuralization predicts
that inhibition of TGFb signaling at any level of the
pathway: extracellularly by sequestering the ligands, at the
membrane level by interfering with the reception of the
signal, or intracellularly by interference with the signal
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transducers leads to the specification of neural fate
(Hemmati-Brivanlou and Melton, 1994). There are now
examples of inhibition at each of these levels. Noggin,
chordin, and follistatin inhibit the ligands extracellularly
(Zimmerman et al., 1996; Piccolo et al., 1996; Yamashita et
al., 1995). Dominant negative receptors such as tBR and
tAR interfere with the reception of the signal at the cell
surface (Hemmati-Brivanlou and Melton, 1992; Graff et al.,
1994; Suzuki et al., 1995). The anti-Smads XSmad7 and
Smad6 (Hata et al., 1998) inhibit signal transduction. All
these treatments result in the adoption of an anterior neural
fate by embryonic cells.
Much has been learned about the biochemical basis of
the inhibitory action of anti-Smads. It is now clear that a
combination of positively and negatively acting Smads
modulate TGFb signaling within embryonic cells. The
integration of these different and sometimes contradic-
tory signals might be mediated through these signal
transducers. It is clear that for members of the TGFb
family shown to be able to act as morphogens, such as
activin and BMP4, the entire repertoire of cell fates
induced by different concentrations of the same ligand
can be mimicked intracellularly by their signal transduc-
ers (Smad1 for BMP4 and Smad2 for activin; Graff et al.,
1996; Wilson et al., 1997; Thomsen, 1996). If XSmad7 can
negatively modulate the activity of Smad1 and Smad2 by
competing for receptor binding or another mechanism, it
is tempting to speculate that the balance between anti-
Smads and effector Smads will play an important role in
the integration of morphogen signals as well.
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